Working together to reduce the global burden of kidney cancer
Kidney cancer is a major public heath challenge, with 1.37 million people currently affected worldwide. In 2022, there were 435,000 new cases diagnosed, and the incidence is projected to rise by more than 71% by 2050.
Click here for shareable information, graphics and materials about kidney cancer for patient organisations worldwide.
2025 Annual Report Now Online
IKCC’s 2025 Annual Report is now available. It is a comprehensive overview of all that was achieved to advance IKCC’s strategic priorities through programs that deliver long-term value to the global kidney cancer community.
Read all about IKCC’s 2025 activities and learn more about the organisation’s vision moving forward here.
World Kidney Cancer Day 2026
Save the date! This year, World Kidney Cancer Day (WKCD) will be on 18 June 2026, marking the 10th year of raising awareness for kidney cancer worldwide!
The 2026 theme is Kidney Cancer and Emotional Wellbeing. Results from findings of the 2025 Global Patient Survey on Kidney Cancer show that 85% of kidney cancer patients experience emotional challenges, yet many never raise these issues with their care team. The 2026 WKCD campaign will aim to raise awareness and also help empower patients to seek the support they need.
Watch for more information about World Kidney Cancer Day in the coming weeks and months to learn more and get involved.
2025 Global Patient Survey
Bringing evidence-based patient experiences and insights to scientific discussions and decision-makers has long been an IKCC priority. This year, IKCC enhanced its attendance at kidney cancer and oncology conferences with the strategic goal of sharing results from the 2025 IKCC Global Patient Survey on Kidney Cancer (GPS) with healthcare professionals and decision makers.
An overview of these efforts is now available, including summaries of the poster presentations, as well as links to the Posters and published abstracts.
Tweets from @IKCCorg
Margie Hickey, member of the Board of Directors, was honoured to represent IKCC at The Max Foundation Think Tank in Seattle. (1/2)
The day focused on innovative and creative approaches designed to help @themaxfndn achieve its ambitious objective of serving 100,000 patients annually by 2031—with the patient voice at the center.
📷: Nick Klein Photography
#IKCC #PatientAdvocacy #GlobalHealth (2/2)
Navigating treatment side effects is a critical part of living with #KidneyCancer.
In a recent episode of Hot Topics in Kidney Health from the National Kidney Foundation, KidneyCAN patient advocate Andrew Allers share insights on managing side effects, recognizing warning signs,
Join us TOMORROW for a free virtual forum on Wilms Tumor & pediatric #kidneycancer. Grateful to have TOP EXPERTS in the field participating to share info/insights with families facing such difficult challenges🧡
🗓️Thursday 4/30 - 11:00-4:30 ET
Register 🔗 https://lnkd.in/eCiM67_V
Webinar Alert!
From medical schedules to hard conversations, parenting with VHL is not easy. This May 6 webinar is built for parents who are living it every day.
Secure your spot here: https://us02web.zoom.us/meeting/register/8C0h7JYFRKmXUjoeB184BA
We’re looking forward to the DISCERN Annual Meeting on 6-7 May. Stay tuned for updates!
Season 5 of Kidney Cancer Unfiltered is officially live!!! 🙌🎙️✨
How do we express the things that feel impossible to put into words? Our host Annamaria Scaccia and Kayla Fulginiti @ElephantsTea dive into the power of creative expression.
🎧 http://shows.acast.com/kidney-cancer-unfiltered
Did you know?
Kidney cancer is often found by accident.
Kidney cancer is the 14th most prevalent cancer worldwide.
About 59 per cent of kidney cancer cases occur in more developed countries.
Our Global Network
IKCC welcomes every organisation that has an interest in kidney cancer and who pledges to conform to our Code of Conduct. We extend an open invitation to become part of this international network.
Join our mailing list
In the newsletter we highlight news about kidney cancer diagnosis and treatment, and other relevant discussions.